Back to news
Poster
Tue. 1 September

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Partager sur

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

 

Authors:

Caradec J., Benderitter P., Nicodeme , Bouillot, Toum J. , Cachia J., Williams, Bullock A. , Foretz M., Deschemin J C., Vaulont S., Viollet B., Hoflack J
Oncodesign SA , University of Oxford, Cochin Institute.

Abstract:

Anemia is a condition characterized by low hemoglobin levels Anemia is observed during tumor development through the release of inflammatory cytokines, which affect iron availability, a key component of red blood cells In recent years, consequences of anemia of cancer in patients is getting growing recognition from a quality of life perspective, as well as its impact on the treatment scheme and hospitalization duration Cancer induced anemia has been identified in 30 of treatment naive cancers (ECAS study, 2011 WHO methodology) The proportion of anemic patients reaches 70 after treatments, such as chemotherapies Current approaches consider erythropoietin derivatives, formulated iron or transfusions, which does not address underlying chronic inflammation Moreover, their use is limited as a consequence of toxicities ( formulated iron) or availability…

Read the others news

Financial
Press Release
Wed. 28 September
Oncodesign and OPM announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access+ market...

Restez informé de l'actualité OPM

Inscrivez-vous à la newsletter pour ne manquer aucune nouveauté !